Technology

Using immunology to transform life-threatening and life-limiting diseases

NovaBiotics’ proprietary technology platforms have been generated through rational drug design principles, using a ‘smart immunology’ approach. These platforms are based on the body’s innate immune defense molecules, aminothiol and peptide first responders of the immune system to infectious and inflammatory challenge. The therapy candidates we have developed from our platforms are ‘supercharged’ versions of these key molecules in combatting respiratory, inflammatory and infectious disease.

Publications

NovaBiotics’ have a number of publications across various platforms. Please click on the link NovaBiotics publications to see the full list including links to view specific publications of interest.

Intellectual Property

NovaBiotics extensive patent estate encompasses the composition, formulation and medical use of our therapy candidates. Our patents are already widely in force across the world with pending and new filings extending patent runways and further bolstering already broad and secure IP protection. All of NovaBiotics IP has been generated in-house and is wholly owned by the company.